TAXUS update supports Boston's DES (drug-eluting stent)
This article was originally published in Clinica
Executive Summary
Follow-up data from Boston Scientific's TAXUS clinical trials of its paclitaxel-eluting coronary stent continue to support the product's safety and efficacy, the company reported at last week's Paris Course on Revascularization, in France.